10 - 12 July 2021
EAACI Hybrid Congress 2021

Industry Section

All Digital only Industry Symposia

Saturday, 10 July 2021

Digital Company Sponsored Symposia (DCSS) /  Digital Satellite Symposia (DSAT) /  Digital Company Sponsored Mini Symposia (DCSMS)

All Digital only Symposia will be made available on the EAACI Hybrid Congress 2021 digital platform.


12:00 - 12:30

Sanofi Genzyme and Regeneron: Type 2 Inflammation: What every clinician should know

How can we most effectively translate the science of Type 2 inflammation into clinically relevant insights that inform management of severe asthma?

Speakers: Hans in ‘t Veen, The Netherlands; Jasper Kappen, The Netherlands


DSAT 1-1

12:45 - 13:45

Novartis: IgE in asthma and nasal polyposis: your questions answered

Chair: Marcus Maurer, Germany

Welcome and introduction

Speaker: Marcus Maurer, Germany

Panel discussion:

Why is it important to consider comorbidities when treating patients with asthma?

Anti-IgE therapy is well established in severe allergic asthma, what do we know
about it in nasal polyposis?

How should physicians choose between the biological agents available?

How important is a multi-disciplinary approach for patients?

Speakers: Enrico Heffler, Italy; Philippe Gevaert, Belgium

DSAT 1-2

12:45 - 13:45

Takeda: Looking ahead to the future: Advances in HAE diagnostics

Chair: Marcus Maurer, Germany

Welcome and introduction to diagnosing HAE

Speaker: Marcus Maurer, Germany

Current tools for diagnosing HAE

Speaker: Henriette Farkas, Hungary

The future of HAE diagnosis

Speaker: Jonathan Bernstein, USA

Live question and answer session

Speakers: Marcus Maurer, Germany; Henriette Farkas, Hungary; Jonathan Bernstein, USA

Closing remarks

Speaker: Marcus Maurer, Germany




14:00 - 14:30

Sanofi Genzyme and Regeneron: CRSwNP, a Type 2 Inflammatory disease: Changing treatment paradigm

CRSwNP as a Type 2 Inflammatory disease: Then and now

Speaker: Claus Bachert, Belgium

Managing CRSwNP: Critical insights into the use of biologics

Speaker: Joaquim Mullol, Spain


14:45 - 15:15

Sanofi Genzyme and Regeneron: Breaking new ground: A closer look at Type 2 Inflammation in pediatric asthma     

Revealing the burden of severe asthma in pediatric populations

Speaker: Leonard Bacharier, USA

Unmasking Type 2 Inflammation in pediatric asthma

Speaker: Nikolaos Papadopoulos, UK

Staying on target: Novel approaches to managing pediatric severe asthma

Speaker: Leonard Bacharier, USA


15:30 - 16:00

Sanofi Genzyme and Regeneron: Exploring the Complexity of Chronic Spontaneous Urticaria                                                     


Chronic Spontaneous Urticaria (CSU): unpredictable, chronic and burdensome          

Speaker: Jonathan Bernstein, USA

CSU has a complex pathophysiology involving autoimmunity, autoallergy, and type 2 inflammation

Speaker: Marcus Maurer, Germany        

Current clinical challenges in CSU            

Speakers: Jonathan Bernstein, USA; Marcus Maurer, Germany

DSAT 1-3

16:15 - 17:15

FAES FARMA and Menarini Group: Clinical Cases in discussion: 3 patients, 3 experts & 1 solution         

Chairs: Pablo Rodriguez, Spain; Fulvio Braido, Italy; Torsten Zuberbier, Germany

Urticaria and Rhinitis in children

Speaker: Pablo Rodriguez, Spain

United Airway Disease, Allergic Rhinitis and its Impact on Asthma

Speaker: Fulvio Braido, Italy        


Speaker: Torsten Zuberbier, Germany


DSAT 1-4

18:00 - 19:00

OM Pharma:  Strengthening the immune system to reduce asthma risk: paving the way to the future? 

Chair: Jonathan Grigg, UK

Welcome & Introduction

Speaker: Jonathan Grigg, UK

Highlights on the concept of innate immune training

Speaker: Alberto Mantovani, Italy

Could therapy with bacterial products prevent asthma?

Speaker: Jonathan Grigg, UK       

How to improve control of infectious asthma exacerbations in adults: state-of-art and future perspectives

Speaker: Gerdien Tramper, The Netherlands      

Roundtable discussion

Speakers: Jonathan Grigg, United Kingdom, Alberto Mantovani, Italy; Gerdien Tramper, The Netherlands

Take-home messages and closing remarks

Speaker: Jonathan Grigg, UK




DCSS 1-1

18:00 - 19:30

Allergy Therapeutics: Pioneering a new age – fighting allergic disease on all fronts!

Chair: Ignacio Dávila, Spain

MCT – an evidence-based adjuvant in allergen immunotherapy

Speaker: Ralph Mösges, Germany

Insect Venom Allergy – exploring the current landscape

Speaker: Thilo Jakob, Germany

Beta-lactoglobulin – from farm stable dust to a lozenge inducing immune resilience in allergic diseases

Speaker: Erika Jensen-Jarolim, Austria


DCSS 1-2

18:00 - 19:30

Aimmune Therapeutics: The treatment of peanut allergy with PALFORZIA®, from clinical development to practical experience        

Chair: Antonella Muraro, Italy                    


Introduction to peanut allergy and PALFORZIA

Speaker: Antonella Muraro, Italy              

PALFORZIA: data review

Speaker: Katharina Blümchen, Germany

PALFORZIA: interpreting the data

Speaker: George du Toit, UK       

PALFORZIA: learning from US practical experience

Speaker: Joel Hartman, USA

DCSS 1-3

18:00 - 19:30

CSL Behring: The Evolving Evidence for the Long-Term, Prophylactic Treatment of Hereditary Angioedema Patients with Subcutaneous C1-INH

Chair: Marcus Maurer, Germany

Welcome and Introductions

Speaker: Marcus Maurer, Germany

Learnings from the HAE Guidelines

Speaker: Markus Magerl, Germany

Examining the Evidence Regarding C1-INH (SC) in All Populations, with an Emphasis on Special Populations

Speaker: Donald Levy, USA

Using Clinical and Real-World Experience to Inform Treatment Decisions

Speaker: Stefan Cimbollek, Spain

Q&A Session, Summary and Close

Speaker: Marcus Maurer, Germany



Sunday, 11 July 2021

DSAT 2-1

08:00 - 09:00

Abbott Laboratories: Expansion of Hydrolysed Rice Formula for Infants with Cow’s Milk Allergy: Considerations for Clinical Practice

Chair: Alessandro Fiocchi,  Italy; Rosan Meyer, UK; Christophe Dupont, France

Welcome and introductions

Speaker: Alessandro Fiocchi,  Italy

Overview of CMA and introducing a hydrolysed rice formula

Speaker: Alessandro Fiocchi,  Italy

Practical experience using hydrolysed rice formula from a gastroenterologist’s perspective

Speaker: Christophe Dupont, France

The dietetic perspective of hydrolysed rice protein formulas

Speaker: Rosan Meyer, UK


Speakers: Alessandro Fiocchi,  Italy; Rosan Meyer, UK; Christophe Dupont, France


DSAT 2-3             

10:00 - 11:00

BioCryst: Rethinking hereditary angioedema: What role can the first oral plasma kallikrein inhibitor play?

Chair: Marcin Stobiecki, Poland


Reflection on hereditary angioedema (HAE): Progress and perspectives

Speaker: Marcin Stobiecki, Poland

A new view: What is the role of an oral plasma kallikrein inhibitor?

Speaker: Emel Aygören-Pürsün, Germany

Changing times: How can we optimise patient transition between therapies?

Speaker: Marcin Stobieck, Poland

From clinical data to real-world evidence: Does the reality match the theory?

Speaker: Delphine Gobert, France

Applied thinking: What can we learn from the evidence?

Speaker: Sorena Kiani, UK

Looking ahead in HAE: What should our vision be?

Speaker: Marcin Stobiecki, Poland



12:00 - 12:30

Sanofi Genzyme and Regeneron: Targeting Type 2 mechanisms in patients with atopic dermatitis and comorbid Type 2 Inflammatory disease: A case-based reflection


Connecting Type 2 Inflammation to clinical characteristics of disease    

Speaker: Mark Boguniewciz, United States


DSAT 2-4

12:45 - 13:45

Novartis: IgE-mediated food allergy: need for a revolution

Chair: Marcus Maurer, Germany


Panel discussion:

Why do we need to be concerned about food allergy?

What is the role of IgE in food allergy?

What have we learned about epitope-specific IgE from the LEAP study?

What are the advances in food allergy diagnostics?

Do current treatment options meet the needs of people with food allergy?

What more can we do together to improve food allergy care?  

Speakers: George du Toit, UK; Hugh Sampson, USA; Alexandra Santos, UK


DSAT 2-5             

12:45 - 13:45

Takeda: Efficacy and quality of life in HAE: The lanadelumab experience

Chair: Waserman Susan, Canada

Welcome and introductions

Speaker: Susan Waserman, Canada

Living with HAE

Speaker: Patient ambassador (name confidential), UK

The true burden of HAE

Speaker: Susan Waserman, Canada

An overview of the efficacy, safety and QoL data from the HELP and HELP OLE studies 

Speaker: Sinisa Savic, UK

Efficacy, safety and QoL in a real-world setting: Experience from France

Speaker: Laurence Bouillet, France

Closing remarks

Speaker: Susan Waserman, Canada



14.00 -14.30

Revenio Research Oy: Re-thinking lung function testing in young children

Chair: Ville-Pekka Seppä, Finland


Pediatric asthma

Speaker: Mika Mäkelä, Finland


14:45 - 15:15

BluePrint Medicines: Systemic Mastocytosis – An Allergist/Immunologist Perspective  

Chair: Vito Sabato, Belgium

Systemic Mastocytosis – An Allergist/Immunologist Perspective

Speaker: Vito Sabato, Belgium


15:30 - 16:00

Sanofi Genzyme and Regeneron: Championing change: Is elimination of oral corticosteroid use in asthma achievable today?                                                    


OCS in patients with uncontrolled asthma: An unaddressed challenge

Speaker: Ian Pavord, UK

Corticosteroid Overload: The Compounding Burden in Patients

Speaker: Tanya Laidlaw, USA

Current Strategies for Reducing Corticosteroid Use: How Far Have We Come?

Speakers: Ian Pavord, United Kingdom; Tanya Laidlaw, USA

Changing the Script: Improving Asthma Management in OCS-Dependent Patients

Speakers: Ian Pavord, United Kingdom; Tanya Laidlaw, USA

DSAT 2-7             

18:15 - 19:15

Purina Institute: A transformational approach to managing allergies to cats

Chair: Antonella Muraro, Italy

A transformational approach to managing allergies to cats - Part I

Speaker: Antonella Muraro, Italy

A transformational approach to managing allergies to cats - Part II

Speaker: Ebenezer Satyaraj, USA


Speaker: Antonella Muraro, Italy


DSAT 2-13           

19:15 - 20:15

Uriach: Mind the PAF: a new route to managing chronic urticaria and allergic diseases?

Chair: Frank Siebenhaar, Germany

Welcome address

Speaker: Frank Siebenhaar, Germany

Introduction to PAF and PAF targeting treatments

Speaker: Frank Siebenhaar, Germany

Targeting PAF in allergic rhinitis: a responder analysis to rupatadine

Speaker: Joaquim Mullol, Spain

Targeting PAF in chronic spontaneous urticaria: a success story

Speaker: Ana M. Giménez-Arnau, Spain

Panel discussion

Speakers: Frank Siebenhaar, Germany; Joaquim Mullol, Spain; Ana M. Giménez-Arnau, Spain

Closing statement

Speaker: Frank Siebenhaar, Germany


Monday, 12 July 2021


12:15 - 12:45

Sanofi Genzyme and Regeneron: Type 2 Asthma and FeNO: The Clinician’s Tool in Precision Treatment                                                


No single biomarker can capture the full spectrum of Type 2 inflammation in asthma.

Clinical utility of FeNO, among other biomarkers, in the management of patients with severe asthma. Illustrated through rea

Speakers. Anh Tuan Dinh-Xuan, France; Stephanie Korn, Germany

DSAT 3-1

13:00 - 14:00

Novartis: Complete control of chronic spontaneous urticaria – mission (im)possible?   

Chair: Marcus Maurer, Germany               

Welcome & Introduction

Speaker: Marcus Maurer, Germany        

Why do our patients fail to reach complete control?

Speaker: Zenon Brzoza, Poland

How can targeting IgE contribute to complete control?

Speaker: Marcus Maurer, Germany

Questions and answers

Speakers: Marcus Maurer, Germany; Zenon Brzoza, Poland

DSAT 3-2

13:00 - 14:00

MSD: Chronic Cough & Refractory Chronic Cough: Preparing for the Future

Chair: Joaquin Sastre, Spain


Opening Remarks

Speaker: Joaquin Sastre, Spain

From Cough in Health to Cough in Disease; the Multiple Pathways

Speaker: Brendan Canning, USA

Facing the Challenge: Diagnosing and Managing Chronic Cough

Speaker: Woo-Jung Song, Korea

Q&A and Panel discussion

Speakers: Joaquin Sastre, Spain; Brendan Canning, USA; Woo-Jung Song, Korea

Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Send feedback